Current Research Trials
Sydney Retina Clinic and Day Surgery is proud to be associated with a research department named the Sydney Institute of Vision Science. All members of the research team have a strong background in both clinical and laboratory research and are dedicated to the development of new treatment for retinal disease.
A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety and Tolerability Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Macular Edema Secondary To Branch Retinal Vein Occlusion
A Randomized, Double-Masked, 48-Week, Parallel-Group, Placebo-Controlled, Proof-Of-Concept Study To Investigate The Efficacy And Safety Of Rg7774 In Patients With Diabetes Mellitus Type 1 Or Type 2 With Treatment-Naïve Diabetic Retinopathy
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Macular Edema Secondary To Central Retinal Or Hemiretinal Vein Occlusion
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
Study of safety and tolerability of intravitreal Fludrocortisone Acetate (FCA) in patients with Geographic Atrophy (GA).
A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety And Tolerability Of Exn407 In Subjects With Centre Involved Diabetic Macular Oedema Secondary To Diabetes Mellitus.
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
A Phase 3 Multicenter, Randomized, Double-Masked, Sham controlled Clinical Trial To Assess The Safety And Efficacy Of Intravitreal Administration Of Zimura™ (Complement C5 Inhibitor) In Patients With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration.
The OTX-TKI study is a phase 1 open-label, dose escalation study of OTX-TKI (axitinib implant) for intravitreal use in subjects with neovascular Age-related macular degeneration (AMD).
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration.
A pilot study of a novel, biodegradable, polymeric vitreous substitute for postoperative retinal tamponade.
A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of Faricimab In Patients With Diabetic Macular Edema
Evaluation of Safety and Efficacy of the IBE-814 Intravitreal Implant in Patients with Diabetic Macular Oedema and Macular Oedema due to Retinal Vein Occlusion
A Phase III Randomized, Double Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics Pharmacokinetics, and Immunogenicity between SCD411 and Eylea ® in Subjects with Neovascular Age -related Macular Degeneration.
Evaluation of an extended and proactive dosing regimen in treatment-naïve patients with wet age-related macular degeneration
Investigator Initiated Studies
Brolucizumab Treatment For Pigment Epithelial Detachment In Treatment-Resistant Neovascular Age Related Macular Degeneration
Clinicopathological Correlation in Macular Degeneration.